Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics has recruited first patient in an open-label, dose escalation Phase I study evaluating LOR-253, the company's small molecular anticancer drug.
Subscribe to our email newsletter
The Phase I study is expected to recruit 22-37 patients with advanced or metastatic solid tumors for which no effective therapy is currently available, or whose cancer has not responded to conventional or standard therapies.
In addition, up to 10 patients will be added at the recommended Phase II dose level for assessment of tumor biomarkers related to the anticancer mechanism of LOR-253.
The primary objectives of the study are to determine the maximum tolerated dose and recommended Phase II dose of LOR-253.
Additional study objectives include the safety profile, anti-tumor activity, and pharmacokinetics of LOR-253.
Lorus president and CEO Aiping Young this is an important milestone for the development of LOR-253, as the first clinical stage drug from our very active small molecule discovery program.